Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
- PMID: 33219491
- PMCID: PMC7678568
- DOI: 10.1007/s10875-020-00904-5
Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Comment in
-
Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia.J Clin Immunol. 2021 Jul;41(5):926-929. doi: 10.1007/s10875-021-00996-7. Epub 2021 Feb 20. J Clin Immunol. 2021. PMID: 33611660 Free PMC article. No abstract available.
References
-
- Collaborative TO, Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv. Cold Spring Harbor Laboratory Press; 2020;2020.05.06.20092999.
-
- Quinti I, Lougaris V, Milito C, Cinetto F, Pecoraro A, Mezzaroma I, Mastroianni CM, Turriziani O, Bondioni MP, Filippini M, Soresina A, Spadaro G, Agostini C, Carsetti R, Plebani A. A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia. J Allergy Clin Immunol. 2020;146:211–213.e4. doi: 10.1016/j.jaci.2020.04.013. - DOI - PMC - PubMed
-
- Soresina A, Moratto D, Chiarini M, Paolillo C, Baresi G, Focà E, Bezzi M, Baronio B, Giacomelli M, Badolato R. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol Off Publ Eur Soc Pediatr Allergy Immunol. 2020;31:565–569. doi: 10.1111/pai.13263. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical